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Chronic myeloid leukemia
Imatinib has so far been the first-choice treatment in chronic myeloid leukemia with excellent results. However,
only a proportion of patients achieve major molecular response – hence the need to find biological predictors of
outcome to select the optimal therapeutic strategy now that more potent inhibitors are available. We investigated
a panel of 20 polymorphisms in seven genes, potentially associated with the pharmacogenetics of imatinib, in a
subset of 189 patients with newly diagnosed chronic myeloid leukemia enrolled in the TOPS trial. The analysis
included polymorphisms in the transporters hOCT1, MDR1, ABCG2, OCTN1, and OATP1A2, and in the metab-
olizing genes CYP3A4 and CYP3A5. In the overall population, the OCTN1 C allele (rs1050152), a simple combi-
nation of polymorphisms in the hOCT1 gene and another combination in the genes involved in imatinib uptake
were significantly associated with major molecular response. The combination of polymorphisms in imatinib
uptake was also significantly associated with complete molecular response. Analyses restricted to Caucasians
highlighted the significant association of MDR1 CC (rs60023214) genotype with complete molecular response.
We demonstrate the usefulness of a pharmacogenetic approach for stratifying patients with chronic myeloid
leukemia according to their likelihood of achieving a major or complete molecular response to imatinib. This rep-
resents an attractive opportunity for therapy optimization, worth testing in clinical trials.
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Introduction 
The introduction of the Bcr-Abl tyrosine kinase inhibitor
imatinib mesylate in the first-line treatment of Philadelphia
chromosome-positive (Ph+) chronic myeloid leukemia (CML)
revolutionized patients’ outcome. Given the excellent hema-
tologic and cytogenetic response rates that can be obtained in
the chronic phase of the disease,1 the goal of CML therapy
has moved to the achievement of a major molecular response
(MMR; defined as a 3-log reduction in Bcr-Abl transcript level
from a standardized baseline value)2 and possibly a complete
molecular response [CMR; defined as at least a 4-log reduc-
tion corresponding to undetectable Bcr-Abl transcript by real-
time reverse transcription polymerase chain reaction (PCR)],2
which might represent an ‘operational cure’ as well as a pre-
requisite for discontinuation of imatinib.3
Research in CML has since focused on finding biological
predictors of response allowing for treatment optimization. It
is well recognized that interpatient variability in drug
response reflects the systemic levels or intracellular concen-
trations of the drug, known to be associated with the pharma-
cokinetics (absorption, distribution, and metabolism) of the
drug itself.4 Imatinib is metabolized by the cytochrome-P450
- mostly CYP3A4 and 3A5 isoforms.5 The active uptake of
imatinib into cells is known to be mediated mainly by the
hOCT1 transporter (encoded by the SLC22A1 gene),6-7
whereas its efflux is mediated by the ABC transporters, in
particular ABCB1 (also known as MDR1) and, to a lesser
extent, ABCG2.6,8-10 Besides these, other transporters may be
important in the absorption, distribution, and elimination of
imatinib, including the families of organic cation transporters
(OCT) and organic anion transporters (OAT). In particular, a
recent study by Hu et al.11 identified imatinib as a substrate of
OATP1A2 (encoded by SLCO1A2), whereas the involvement
of members of the OCTN family as imatinib transporters is
still uncertain.
Interpatient variability in imatinib metabolism/transport is
substantial and thus far unexplained. A possibility is that
genetic polymorphisms in genes encoding imatinib-metabo-
lizing enzymes and transporters may influence the extent to
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which imatinib is delivered to target cells. Accordingly,
genetic polymorphisms of the candidate genes
CYP3A4/3A5, MDR1, ABCG2, OATP1A2, OCTN1 (encod-
ed by SLC22A4) and hOCT1 could affect expression of
corresponding proteins and thus may predict differences
in responses to imatinib. To explore this hypothesis, we
selected a panel of polymorphisms in these genes and
genotyped 189 newly diagnosed CML patients treated
with imatinib in the framework of the Tyrosine kinase
OPtimization and Selectivity (TOPS) phase III trial.12
Design and Methods
Study population
A total of 189 CML patients receiving imatinib were retrospec-
tively enrolled in this pharmacogenetic study. These patients rep-
resented a subset of the population of the TOPS trial - a random-
ized, phase III study of imatinib 400 mg/day versus imatinib 800
mg/day in newly diagnosed and previously untreated CML
patients in chronic phase.12 The patients’ selection was based
exclusively on availability of written informed consent for correl-
ative sub-studies, according to the Helsinki Declaration and its
later amendments, and sufficient amount of archived material.
The study was approved by all local ethical committees. The
patients’ characteristics and treatment protocol have been
described elsewhere.12 Table 1 summarizes selected demographic
characteristics of our study population.
Evaluation of response to imatinib
Molecular response (MR) was classified based on BCR-ABL to
control gene transcript ratios, expressed on the International
Scale.13 MMR and CMR were defined as ratios ≤0.1% and
≤0.0032%, respectively. Cytogenetic response (CgR) based on
bone marrow assessment was classified as complete (CCgR; 0%
Ph+ cells), partial (PCgR; >0 to 35% Ph+ cells), minor (>35 to 65%
Ph+ cells), minimal (> 65 to 95% Ph+ cells), and none (>95 to 100%
Ph+ cells). A major cytogenetic response (MCgR) was defined as
achieving either a CCgR or a PCgR. Time to response (MMR,
CMR, MCgR, CCgR) was defined as the interval between the date
of randomization and the first date of achieving a response.
Patients who progressed to accelerated phase or blast crisis were
classified as non-responders at all time points.
Genotyping analysis
DNA was extracted from cryopreserved white blood cells using
conventional methods. The characteristics of the studied polymor-
phisms (one insertion/deletion and 19 single nucleotide polymor-
phisms, from here on all referred to as SNP in the text) are reported
in Online Supplementary Table S1. Genotypes were determined by
PCR-based assays (restriction fragment length polymorphism
and/or real-time) according to published methods,14-20 or as recom-
mended by the manufacturer (Online Supplementary Table S1).
Positive and negative controls were included in each reaction as
quality controls. In addition, the accuracy of genotyping was con-
firmed by repetition of 100% of the samples. The replicates were
100% concordant.
Statistical analysis
Genotype distribution – overall and by race – was tested for
Hardy-Weinberg equilibrium (HWE) with exact tests.21 The asso-
ciation of individual SNP with MMR, CMR, MCgR, and CCgR
was assessed using the exact P-value based on a Cochran-
Armitage trend test in an additive model with the number of
minor alleles (0, 1, or 2) as the predictor. Survival analyses were
also used to examine the relationship between SNP and MMR,
CMR, MCgR, and CCgR. Time to response was defined as the
interval between randomization and the date of first confirmed
response for any of the given response variables under study. The
follow-up time was censored at the date of last assessment for
those not achieving a response. Hazard ratios were estimated with
Cox proportional hazards models and evaluated with likelihood
ratio tests. Dose of imatinib was included as a covariate in the
models to adjust for possible differential response in the two ima-
tinib dose groups. Statistically significant associations observed in
the Cox regression analyses were further evaluated through plots
based on the Kaplan-Meier method. The Kaplan-Meier curves
were compared with log-rank tests of trend, assuming an additive
genetic model. Haplotype frequencies were estimated using the
expectation-maximization algorithm. Linkage disequilibrium
between pairs of SP was estimated with Lewontin’s D′, and like-
lihood ratio tests were performed to assess linkage disequilibrium
among multiple loci. Empirical P-values obtained from permuta-
tion tests (n = 10,000 permutations) were used to evaluate the
association between haplotypes and imatinib response at 12
months. All statistical tests were two-sided, with statistical signif-
icance defined as P<0.05. No adjustments were made for multiple
comparisons. Statistical analyses were conducted using SAS ver-
sion 9.1 (SAS Institute Inc., Cary, NC, USA).
The primary purpose of this study was to evaluate the effect of
individual SNP on response to imatinib therapy. As an exploratory
analysis, we also examined simple summary measures of func-
tionally related (uptake and efflux) SNP. These were defined as the
number of alleles, across the genes of interest, hypothesized or
found in this study to be associated with a favorable response.
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Table 1. Patients’ and disease characteristics of the study population.
SNP study (N=189)
Gender, N. (%)
Female 86 (45.5)
Male 103 (54.5)
Age, median (range) 46 (18 - 75)
Race, N. (%)
Caucasian* (%) 156 (82.5)
Asian (%) 23 (12.2)
Other** (%) 10 (5.3)
Sokal risk group, N. (%)
Low 84 (44.4)
Intermediate 65 (34.4)
High 40 (21.2)
Cytogenetics, N. (%)***
t(9;22) only 158 (86.3)
Additional abnormalities 25 (13.7)
Imatinib dose randomization group, N. (%)
400 mg/die 53 (28.0)
800 mg/die 136 (72.0)
MMR at 12 months (as defined in 12)
Yes (%) 96 (50.8)
No (%) 93 (49.2)
Response by 12 months based on time 
to event analysis, % achieving (95% CI)
MMR 67% (60%,73%)
CMR 9% (5%,14%)
MCgR 82% (75%,87%)
CCgR 76% (70%,83%)
*Caucasians included a European population (n > 41 patients), North Americans (pri-
marily USA; n > 65) and Australians (n=50). **Non white, non-Asian. ***Data unavail-
able for six patients.
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According to the results of in vitro studies reported in the literature,
we hypothesized a favorable response in the presence of hOCT1
rs4646277, rs4646278, and rs2282143, MDR1 rs1128503 (also
known as C1236T), rs60023214 (also known as C3435T),
rs1128501, and rs10245483 and OATP1A2 rs11568563 major alle-
les and ABCG2 rs2231137 and rs2231142 variant alleles.21 No func-
tional knowledge was available for the remaining SNP and the
major allele was thus hypothesized to be associated with favor-
able response unless the present study suggested a different rela-
tionship.
Results
Genotype distribution
Genotype distributions of the 20 candidate SNP are
summarized in Online Supplementary Table S2A-C. Five
SNP (hOCT1: rs4646277, rs4646278; MDR1: rs1128501;
CYP3A4: rs28371759 and CYP3A5: rs28365083) were
homozygous for the major allele for all patients and were
excluded from the analyses. The comparison of genotype
frequencies according to the patients’ demographic char-
acteristics revealed differences between Asian and
Caucasian subgroups (Online Supplementary Table S2A, B).
For this reason analyses of associations of SNP with
response restricted to Caucasians were performed in addi-
tion to analyses based on all patients. A deviation from the
HWE was observed for a single SNP (MDR1 rs10245483)
in the Caucasian population; no departures from the HWE
were observed for any other SNP, either in the overall pop-
ulation or in Caucasians. When restricting the analysis to
the Caucasian population, the genotype distributions of
MDR1 rs60023214 and rs2032582 (known as G2677T/A),
CYP3A4 rs2740574 and CYP3A5 rs776746 differed signifi-
cantly by geographical region. However, none of the four
genotypes in the overall Caucasian group showed devia-
tion from the HWE.
Outcomes of imatinib therapy
Treatment outcomes for all patients and only the
Caucasians are presented in Figure 1. With a median total
follow-up of 29 months among the entire study popula-
tion, the 12-month post-randomization cumulative inci-
dences of MMR, CMR, MCgR and CCgR were 67% (95%
CI, 60%-73%), 9% (5%-14%), 82% (75%-87%), and
76% (70%-83%), respectively. Response rates in the
Caucasian subgroup were similar.
Outcomes of imatinib therapy according to candidate
genotypes.
Treatment outcomes were compared according to: (i)
each candidate genotype, (ii) summary measures based on
combinations of SNP in the same gene, and (iii) summary
measures based on combinations of SNP in functionally
related (uptake and efflux) genes. Results of associations
with CgR and MR, adjusted for imatinib dose, among all
patients are grouped in Online Supplementary Table S3. All
the most relevant results estimated with Cox proportional
hazard models and evaluated with likelihood ratio tests
are presented in Table 2.
As far as MR was concerned, presence of the C allele in
OCTN1 (rs1050152) had a favorable impact on MMR
achievement (P=0.03). Nearly significant associations
were observed for the presence of MDR1 A (rs3213619)
and MDR1 C (rs60023214) alleles with achievement of
CMR (P=0.07 and P=0.06 respectively). With respect to
the summary measures, a combination of SNP in the
hOCT1 gene (see Online Supplementary Table S4 for combi-
nation design and distribution in the study population)
was significantly correlated with MMR (P=0.03). The
same combination had a weak effect on CMR achieve-
ment (P=0.08). When considering summary measures of
uptake (see Online Supplementary Table S5 for combination
design and distribution in the study population) and
efflux, only the former was associated with both MMR
and CMR (P=0.004 and P=0.01, respectively).
As far as CgR was concerned, hOCT1 C (rs2282143)
was significantly associated with MCgR (P=0.05); nearly
significant associations were observed for the presence of
MDR1 A (rs3213619) and OCTN1 C (rs1050152) alleles
with achievement of MCgR (P=0.06 for both).
We also carried out analyses limited to Caucasian
SNP genotyping in CML patients
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Figure 1. Rates of cytogenetic and molecular response to imatinib in the study population. Cumulative incidence of patients achieving major
cytogenetic response (MCgR), complete cytogenetic response (CCgR), major molecular response (MMR) and complete molecular response
(CMR) in the overall population (left panel) and in Caucasians (right panel).
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patients, our most representative sample set. All the
results are presented in Online Supplementary Table S6,
while the most relevant ones are grouped in Table 3. The
analyses yielded results similar to those observed in the
overall population. In particular, the presence of OCTN1C
(rs1050152) allele had a significantly favorable impact on
achievement of MMR and a weak effect on CMR (P=0.03
and P=0.07, respectively). A combination of SNP in
hOCT1 (Online Supplementary Table S4) was again associ-
ated with achievement of MMR (P=0.05). Similarly,
achievement of MMR and CMR is associated with an
increasing number of favorable alleles in genes functional-
ly related to imatinib uptake (Table 3; P=0.01 for both). In
addition to these results, the analyses in the Caucasian
subgroup pointed out the influence of two additional SNP
on the achievement of MR. The CC genotype in MDR1
(rs60023214) was significantly associated with MMR
achievement (P=0.005), and a similar tendency was
observed for the achievement of CMR (P=0.09). A nearly
significant association between CYP3A4 GG genotype
(rs270574) and MMR achievement was also observed
(P=0.07). None of the analyzed SNP or combination of
SNP was associated with MCgR or CCgR. 
Plots of the estimated fraction of patients achieving
response by time since treatment initiation based on the
Kaplan-Meier method were analyzed in the overall popu-
lation and separately for Caucasians. Presence of the
minor allele in OCTN1 (TT rs1050152), was associated
with decreased rate of MMR in the overall population and
Caucasians (P=0.028 and P=0.027, respectively; Figure 2).
Results were similar for CMR, and in general the curves
separated at later times compared to those for MMR
(Figure 2). Similarly, the combination of favorable alleles in
the genes involved in imatinib uptake was associated with
increased rates of both MMR and CMR (P=0.004 and
P=0.015, respectively, in the overall population, and
P=0.005 and P=0.009, respectively, in Caucasians). In addi-
tion, an increase in the number of favorable alleles in the
hOCT1 gene was associated with an increased MMR rate
(P=0.030 and P=0.043 in the overall population and
Caucasians, respectively).
In addition to these results, the analyses in the
Caucasian subgroup confirmed the influence of two addi-
tional SNP on MR. The major allele in MDR1 (CC-
rs60023214) was significantly associated with a higher
rate of CMR and had a weak effect on MMR (P=0.005 and
P=0.081, respectively; Figure 3A). The major allele in
CYP3A4 (AA rs2740574) was associated with a decreased
rate of MMR (P=0.038; Figure 3B).
As previously reported, the three MDR1 polymor-
phisms rs1129503 (C1236T), rs2032582 (G2677T/A), and
rs60023214 (C3435T), were found to be in strong linkage
disequilibrium (rs1129503 and rs2032582: D′=0.76;
rs1129503 and rs60023214: D′=0.51; rs2032582 and
rs60023214: D′=0.61; test for linkage disequilibrium
among the three markers P<0.0001). However none of the
s. angelini et al.
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Table 2. Most relevant correlations between treatment outcomes and candidate genotypes or SNP combinations in the overall population.
Outcomes Gene, rs number Referent genotype Adverse genotype MAF* P Hazard ratio [95% CI] **
MMR OCTN1 - rs1050152 CC or CT TT 0.38 0.03 0.79 (0.63, 0.98)
CMR MDR1 - rs3213619 AA AG or GG 0.03 0.07 2.27 (1.03, 5.00)
CMR MDR1 - rs60023214 CC CT or TT 0.45 0.06 0.70 (0.49, 1.02)
MMR hOCT1 - SNP combination - - - 0.03 1.23 (1.01, 1.50)
CMR hOCT1 - SNP combination - - - 0.08 1.31 (0.96, 1.79)
MMR Uptake - SNP combination - - - 0.004 1.21 (1.06, 1.37)
CMR Uptake - SNP combination - - - 0.01 1.30 (1.05, 1.61)
MCgR hOCT1 - rs2282143 CC CT or TT 0.03 0.05 1.87 (1.06, 3.29)
MCgR MDR1 - rs3213619 AA AG or GG 0.03 0.06 1.92 (1.03, 3.56)
CCgR MDR1 - rs3213619 AA AG or GG 0.03 0.07 1.85 (0.99, 3.44)
MCgR OCTN1 - rs1050152 CC or CT TT 0.38 0.06 0.81 (0.65, 1.01)
*MAF: minor allele frequency;** Hazard ratio estimates adjusted for randomized drug dose.
Table 3. Most relevant correlations between treatment outcomes and candidate genotypes or SNP combinations among Caucasians.
Outcomes Gene, rs number Referent genotype Adverse genotype MAF* P Hazard ratio [95% CI] **
MMR hOCT1 - rs2282143 CC CT or TT 0.01 0.08 0.25 (0.03, 1.79)
MMR MDR1 - rs60023214 CC CT or TT 0.49 0.09 0.79 (0.60, 1.04)
CMR MDR1 - rs60023214 CC CT or TT 0.49 0.005 0.56 (0.37, 0.84)
CMR MDR1 - rs3213619 AA AG or GG 0.02 0.08 2.78 (1.01, 8.02)
MMR OCTN1 - rs1050152 CC or CT TT 0.44 0.03 0.77 (0.61, 0.97)
CMR OCTN1 - rs1050152 CC or CT TT 0.44 0.07 0.70 (0.48, 1.03)
MMR CYP3A4 – rs2740574 GG AG or AA 0.05 0.07 1.78 (1.00, 3.17)
MMR hOCT1- SNP combination - - - 0.05 1.24 (1.00, 1.53)
MMR Uptake - SNP combination - - - 0.01 1.23 (1.06, 1.44)
CMR Uptake - SNP combination - - - 0.01 1.37 (1.08, 1.75)
*MAF: minor allele frequency; ** Hazard ratio estimates adjusted for randomized drug dose.
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resulting haplotypes (see Online Supplementary Table S7 for
haplotype frequencies) was associated with response to
imatinib.
Analogous analyses were performed for loss of MMR,
MCgR, and CCgR. However, the loss of response rates
was quite low and no suggestion of association could be
detected.
Analyses were also performed for evidence of differ-
ences by drug dose (imatinib 400 mg versus 800 mg), but
no statistically significant associations were observed.
Discussion
The spectrum of therapeutic options for CML patients
has recently been enriched by second-generation tyrosine
kinase inhibitors that are more potent and/or more selec-
tive than imatinib in Bcr-Abl inhibition. Nilotinib and
dasatinib had already demonstrated remarkable efficacy in
imatinib-resistant cases22,23 and phase II and III studies in
newly diagnosed patients have shown even higher rates of
responses, obtained earlier during therapy, than those
achievable with imatinib.24-27 Paradoxically, the availability
of multiple therapeutic options is not paralleled by the
availability of biological predictors of outcome enabling
identification, at the time of diagnosis, of those patients
who are more likely to benefit from nilotinib or dasatinib
rather than from imatinib - hence there is still a need for
CML treatment optimization. To this end, a refined strat-
ification of patients in terms of likelihood of achieving
MMR, or even better CMR, would be the necessary start-
ing point. Despite intensive research efforts, for years the
Sokal score has been the only reliable factor for risk pre-
diction at the time of diagnosis. Only recently has pre-
therapy hOCT1 transporter activity been demonstrated to
correlate with MMR and to predict for long-term risk of
resistance to imatinib.28,29
In several pathological conditions, pharmacogenetics
has proven to be a potential source of biomarkers given
the known influence of polymorphisms in key genes
encoding drug transporters and metabolizing enzymes on
intracellular drug delivery and, therefore, on the effective-
ness of the drugs. In CML, only three studies had so far
explored this field, but they all suffered from the limita-
tion of being conducted in heterogeneous populations
including patients at different stages of disease, not all
treated with imatinib first-line30,31 and of having limited
sample sizes.32,33
In the present study, we investigated a panel of poly-
morphisms that can be hypothesized to influence imatinib
SNP genotyping in CML patients
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Figure 2. Molecular response by OCTN1 genotype. Cumulative incidence of patients achieving MMR and CMR according to OCTN1
rs1050152 genotype in the overall population (left panels) and in Caucasians (right panels). Given that the major allele is C and the minor
allele is T, CC and CT carriers had significantly higher MMR and CMR rates with respect to TT carriers.
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transport and metabolism in a large series of newly diag-
nosed, previously untreated CML patients receiving ima-
tinib in the framework of the TOPS phase III trial. This is
a worldwide trial that enrolled patients of different ethnic
origin – which brings benefit to the search for common
genetic traits of response. We found, using a multiple can-
didate gene-SNP approach, that there are genes in the ima-
tinib metabolism and transport pathways that are associ-
ated with the degree of MR to imatinib therapy.
Examining multiple candidate genes (20 SNP in 7 genes
associated with imatinib metabolism and transport) also
enables the potential effects of gene-gene interactions to
be assessed.
In this study, a combination of SNP in hOCT1 was sig-
nificantly associated with MMR, regardless of ethnicity.
This finding is biologically plausible, especially in the light
of the fact that all the studied variants are in the coding
region and lead to an amino acid change, assigning a puta-
tive functional role to these SNP. It has been demonstrated
that hOCT1 activity is an important determinant of MR to
imatinib in CML patients.28,34 It is, therefore, reasonable to
expect that a combination of SNP may influence hOCT1
expression and/or activity, thus playing a role in the
achievement of MMR. It remains an open question
whether hOCT1 genotypes determine the levels of
hOCT1 mRNA transcript or alter the transporter
activity/selectivity – thus further studies are warranted in
order to elucidate the correlation of hOCT1 genotypes and
activity. Another combination of SNP, all non-synony-
mous - in genes involved in imatinib uptake (hOCT1,
OCTN1, OATP1A2) - was even more significantly associ-
ated with both MMR and CMR, regardless of ethnicity.
This finding, also biologically plausible, shows the impor-
tance of individual pharmacokinetic differences for the
response to imatinib therapy. Indeed, interindividual vari-
ation in imatinib uptake can be considered as a complex
phenotypic trait, which can most probably be explained as
a complex genotypic feature (i.e. one SNP versus a combi-
nation of SNP). However, little or no functional data are
available in the literature for these SNP, so we can only
hypothesize an effect on imatinib pharmacokinetics based
on the fact that they all correspond to an amino acid vari-
ation in the protein sequence. An interesting finding was
that the OCTN1 rs1050152-C allele was significantly asso-
ciated with MMR in both the overall population and
Caucasians. As far as we are aware, none of the pharma-
cokinetic studies of imatinib has pointed out an involve-
ment of the OCTN1 protein in imatinib transport; howev-
er, it cannot be excluded that this transporter is directly or
indirectly involved in imatinib uptake. It is also possible
that this association occurred by chance - making it essen-
tial to replicate the observation in an independent dataset,
as well as to carry out further in vitro studies assessing
what role OCTN1 may play in the cellular uptake of ima-
tinib.
Our analyses in the Caucasian population also ascribed
a role to an MDR1 polymorphism in the achievement of
CMR, confirming that this transporter may be a critical
determinant of intracellular imatinib levels. Several phar-
macogenetic association studies have focused on MDR1
variants. In particular the role of three variants: rs1128503,
rs60023214, and rs2032582 – better known from pub-
lished studies as C1236T, C3435T and G2677T/A – has
been extensively studied, with strikingly contrasting
results. Dulucq et al.30 were the first to report an associa-
tion between MDR1 rs2032582 (TT), rs1128503 (TT/TA)
and higher MMR rates. They also found that the haplo-
type rs1128503 C, rs2032582 G, rs60023214 C was statis-
tically linked to less frequent MMR. A subsequent study
by Kim et al. could not replicate any of these observations
– no association emerged between any of the MDR1 gene
polymorphisms analyzed and clinical outcome; however,
no haplotype was assessed.31 More recently, Ni et al.32
reported that the rate of resistance to imatinib was higher
in patients carrying the rs1128503 TT variant. Maffioli et
al.33 reported a protective effect from primary failure for
the rs2032582 T allele, however the rs1128503, rs2032582,
rs60023214 TGC haplotype - differing only by one allele
from the one reported by Dulucq et al.30 as favorable - was
more frequently found in patients with primary resistance
to imatinib. 
In our data set, MDR1 haplotypes were not associated
with imatinib response. On the other hand, we found a sta-
tistically significant correlation between MDR1 rs60023214
and CMR. Functional studies35,36 have shown a key role for
rs60023214 in the altered expression and in vivo activity of
s. angelini et al.
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Figure 3. Molecular response in Caucasians according to MDR1 and
CYP3A4 genotypes. (A) Cumulative incidence of patients achieving
CMR according to MDR1 rs60023214 genotype. Given that for
rs60023214 the major allele is C and the minor allele is T, CC car-
riers had a significantly higher CMR rate with respect to CT and TT
carriers. (B) Cumulative incidence of patients achieving MMR
according to CYP3A4 rs2740574 genotype. Given that for
rs2740574 the major allele is A and the minor allele is G, AA carri-
ers had a significantly higher MMR rate with respect to AG carriers
(no GG carriers were detected in our study population).
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P-glycoprotein, product of the MDR1 gene. However, our
data showed a significantly higher CMR rate in carriers of
the CC genotype than in carriers of the CT/TT genotypes,
while results of these studies – the T allele has been report-
ed to be associated with lower transcript levels as com-
pared with the C allele – would suggest the opposite. Our
observations are in agreement with the findings of Ni et al.32
who reported that the rate of resistance was higher in
CT/TT genotype carriers than in CC genotype carriers, and
in disagreement with Maffioli et al.33 In this latter study, the
CC genotype was associated with a higher probability of
primary treatment failure, but the results need to be consid-
ered with caution as only four patients experienced pri-
mary treatment failure. Another critical issue to bear in
mind is that definitions of MR as well as of resistance to
imatinib in CML have only recently been standardized; this
unfortunately represents a confounding element, actually
making it impossible to compare results in terms of associ-
ations across different pharmacogenetic studies. However,
taken together these results suggest that MDR1 is, directly
or indirectly, an important determinant of intracellular ima-
tinib concentration. 
Another interesting finding, restricted to the Caucasian
group, is the significant association between the CYP3A4
rs270574-GG minor allele and increased MMR rate.
Cytochrome P450 isoform 3A4 is generally regarded as
the major enzyme responsible for the metabolism of ima-
tinib.37,38 The rs270574 SNP is located in the regulatory
region of the gene and might, therefore, alter transcrip-
tional activity, ultimately influencing enzyme expression.
To date, there have been no studies addressing the func-
tional implications of this specific polymorphism in vivo;
however, in vitro experiments have suggested that the vari-
ant allele may be associated with higher CYP3A4 expres-
sion.39,40 Pharmacokinetic and pharmacodynamic assess-
ments in the phase I study of imatinib in CML proposed
that variability in CYP3A4 activity might, at least in part,
account for the observed interpatient variability in drug
exposure and that co-administration of drugs inducing
CYP3A4 could increase imatinib metabolism and lead to
low/ineffective imatinib plasma levels.41 One would thus
expect lower response rates to be associated with the
rs270574 variant – which actually contrasts with our find-
ings. On the other hand, a recent study in CML investigat-
ing the influence of in vivo CYP3A4 activity on the
achievement of MR to imatinib found that higher activity
significantly correlated with higher CMR rates at 12
months.42 This observation, in line with our findings,
might have a rationale in the fact that the main imatinib
metabolite formed by CYP3A4, the N-desmethylated
piperazine derivative (CGP74588), is pharmacologically
active, with a potency and selectivity similar to those of
imatinib,37,38 and longer terminal half-life.43,44 It may be
hypothesized that the presence of the variant allele leads
to a larger amount of CGP74588. Another intriguing
hypothesis is that CGP74588 can be subjected to a differ-
ent transport process – which would be in line with the
observation of higher cellular uptake of CGP74588 as
compared to imatinib made by le Coutre et al.44 Obviously
no definitive explanation can be given and further studies
on the pharmacokinetics of CGP74588 are needed. 
The study of combinations of SNP to assess response to
imatinib therapy provides only a preliminary examination
of the potential for creation of a panel of markers to drive
treatment decisions. Creation of such a panel of markers
will require larger sample sizes for development followed
by testing in an independent set.
In conclusion, this study showed that genotyping
should be taken into account in CML patients in an
attempt to individualize treatment further, with the aim of
enhancing efficacy in terms of achievement of MMR and
CMR. On the basis of these findings, stratification of
patients according to genotypes may be proposed for
selection between imatinib and second-generation tyro-
sine kinase inhibitors, and represents an attractive oppor-
tunity for new clinical trials.
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